Unavailable
Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $COO
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/29/2024 | $115.00 → $120.00 | Overweight | Piper Sandler |
7/16/2024 | $107.00 → $115.00 | Hold → Buy | Jefferies |
3/19/2024 | $125.00 | Neutral → Buy | Redburn Atlantic |
3/13/2024 | $100.00 → $120.00 | Neutral → Overweight | JP Morgan |
2/6/2024 | Sector Weight | KeyBanc Capital Markets | |
10/30/2023 | $380.00 | Buy | BofA Securities |
10/5/2023 | $390.00 → $343.00 | Overweight → Neutral | Redburn Atlantic |
5/30/2023 | $410.00 | Equal-Weight | Morgan Stanley |
CooperCompanies Announces First Quarter 2025 Results
SAN RAMON, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended January 31, 2025. Revenue increased 4% year-over-year to $964.7 million. CooperVision (CVI) revenue up 4% to $646.1 million, and CooperSurgical (CSI) revenue up 3% to $318.6 million.GAAP diluted earnings per share (EPS) of $0.52, up $0.11 from last year's first quarter.Non-GAAP diluted EPS of $0.92, up $0.07 from last year's first quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. Commenting on the results, Al White, Cooper's President and CEO said, "We started the y
CooperCompanies Announces Release Date for First Quarter 2025
SAN RAMON, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO) today announced it will report first quarter 2025 financial results on Thursday, March 6, 2025, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 7466264. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two business unit
CooperCompanies to Present at the J.P. Morgan Healthcare Conference
SAN RAMON, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, today announced it will participate at the J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025. Al White, President and CEO, will represent the Company in a session scheduled to begin at 6:00 PM ET. A live and archived webcast of this event, where applicable, will be available by accessing the CooperCompanies' website at http://investor.coopercos.com. About CooperCompanies CooperCompanies (NASDAQ:COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates through two business units, CooperVision and Coop
Piper Sandler reiterated coverage on Cooper with a new price target
Piper Sandler reiterated coverage of Cooper with a rating of Overweight and set a new price target of $120.00 from $115.00 previously
Cooper upgraded by Jefferies with a new price target
Jefferies upgraded Cooper from Hold to Buy and set a new price target of $115.00 from $107.00 previously
Cooper upgraded by Redburn Atlantic with a new price target
Redburn Atlantic upgraded Cooper from Neutral to Buy and set a new price target of $125.00
EVP & Chief Operating Officer Mcbride Daniel G converted options into 22,777 shares and covered exercise/tax liability with 11,567 shares, increasing direct ownership by 23% to 60,120 units (SEC Form 4)
4 - COOPER COMPANIES, INC. (0000711404) (Issuer)
President & CEO White Albert G Iii converted options into 84,264 shares and covered exercise/tax liability with 42,790 shares, increasing direct ownership by 24% to 216,151 units (SEC Form 4)
4 - COOPER COMPANIES, INC. (0000711404) (Issuer)
EVP, CFO & Treasurer Andrews Brian G converted options into 16,850 shares and covered exercise/tax liability with 8,557 shares, increasing direct ownership by 125% to 14,907 units (SEC Form 4)
4 - COOPER COMPANIES, INC. (0000711404) (Issuer)
SEC Form 10-Q filed by The Cooper Companies Inc.
10-Q - COOPER COMPANIES, INC. (0000711404) (Filer)
SEC Form 8-K filed by The Cooper Companies Inc.
8-K - COOPER COMPANIES, INC. (0000711404) (Filer)
SEC Form DEFA14A filed by The Cooper Companies Inc.
DEFA14A - COOPER COMPANIES, INC. (0000711404) (Filer)
Evolus Announces Appointment of Albert G. White III to Board of Directors
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Albert G. White III, President and Chief Executive Officer of The Cooper Companies, Inc. to the Evolus Board of Directors, effective July 1. Mr. White will also serve as a member of Evolus' Compensation Committee. "We are pleased to welcome Al White to the Evolus Board," said Vik Malik, Chairman of the Board of Directors. "Al's extensive leadership experience, industry knowledge, and proven track record of building a leading medical technology company will be a valuable resource as Evolus embarks on a path from a single-product aes
CooperCompanies Appoints Lawrence E. Kurzius to Board of Directors
SAN RAMON, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO) announced today that its Board of Directors has appointed Lawrence E. Kurzius as an independent director, effective December 1, 2023. Kurzius has also been appointed to serve on the Audit Committee and Organization & Compensation Committee when he joins the Board. "We are thrilled to welcome Lawrence to our Board of Directors," said Al White, President and CEO. "His track record of successfully leading a complex, multinational organization will be extremely valuable to CooperCompanies as we continue to drive global growth at CooperVision and CooperSurgical." Kurzius served as Chief Executive Officer of McCo
CooperCompanies Appoints Cynthia Lucchese to Board of Directors
SAN RAMON, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE:COO) announced today that its Board of Directors has appointed Cynthia Lucchese as an independent director, effective October 1, 2022. Lucchese has also been appointed to serve on the Audit Committee and Corporate Governance and Nominating Committee when she joins the Board. "We are pleased to welcome Cindy to Cooper's Board of Directors," said Al White, President and CEO of CooperCompanies. "She is a highly successful executive with a strong strategic, financial, and operational background. We are confident that her business acumen and board experiences will benefit Cooper and our shareholders." Lucchese currentl
CooperCompanies Announces First Quarter 2025 Results
SAN RAMON, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended January 31, 2025. Revenue increased 4% year-over-year to $964.7 million. CooperVision (CVI) revenue up 4% to $646.1 million, and CooperSurgical (CSI) revenue up 3% to $318.6 million.GAAP diluted earnings per share (EPS) of $0.52, up $0.11 from last year's first quarter.Non-GAAP diluted EPS of $0.92, up $0.07 from last year's first quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. Commenting on the results, Al White, Cooper's President and CEO said, "We started the y
CooperCompanies Announces Release Date for First Quarter 2025
SAN RAMON, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO) today announced it will report first quarter 2025 financial results on Thursday, March 6, 2025, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 7466264. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two business unit
CooperCompanies Announces Fourth Quarter and Full Year 2024 Results
SAN RAMON, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal fourth quarter and full year ended October 31, 2024. Fourth quarter 2024 revenue of $1,018.4 million, up 10%, or up 7% organically. Fiscal year 2024 revenue of $3.9 billion, up 8%, or up 8% organically.Fourth quarter 2024 GAAP diluted earnings per share (EPS) of $0.58, up 38%. Fiscal 2024 GAAP diluted EPS of $1.96, up 33%.Fourth quarter 2024 non-GAAP diluted EPS of $1.04, up 19%. Fiscal 2024 non-GAAP diluted EPS of $3.69, up 15%. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. Commenting o
SEC Form SC 13G/A filed by The Cooper Companies Inc. (Amendment)
SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)
SEC Form SC 13G filed by The Cooper Companies Inc.
SC 13G - COOPER COMPANIES, INC. (0000711404) (Subject)
SEC Form SC 13G/A filed by The Cooper Companies Inc. (Amendment)
SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)